Summary: This executive summary showcases critical considerations and strategies for dosing lipid formulations in preclinical models, along with an overview of the regulatory and technical nuances involved in advancing preclinical lipid-based formulations (LBF) to viable clinical dosage forms.
Summary: In this interview with Pharmtech, Karunakar Sukuru, Global Vice President, Rx Product Development, Pharma and Consumer Health, Catalent shares his thoughts on the key benefits of Lipid based formulations (LBF.)
Summary: This executive summary showcases examples of real-life tactical and operational decisions involved in the integrated approach to drug development.
Summary: Download this fact sheet to learn more about our experience and expertise with nitrosamines testing.
Summary: Catalent’s Nottingham facility specializes in early phase development of small molecule drug candidates and complex molecules from bench to clinic through integrated offerings such as…
Summary: In this webinar, experts will discuss the advantages of LBFs and softgels while addressing the ongoing challenges in realizing their full clinical and commercial potential.
